TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07616856: Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry

Sponsor: Lumicell, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 1500 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07616856 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07616856 Rescue Dossier →